341 related articles for article (PubMed ID: 18716130)
21. Creation of a mouse expressing defective human factor IX.
Jin DY; Zhang TP; Gui T; Stafford DW; Monahan PE
Blood; 2004 Sep; 104(6):1733-9. PubMed ID: 15178576
[TBL] [Abstract][Full Text] [Related]
22. Timely and large dose of clotting factor IX provides better joint wound healing after hemarthrosis in hemophilia B mice.
He P; Zhang F; Zhong C; Li M; Zheng J; Hua B; Sun J
Int J Hematol; 2019 Jul; 110(1):59-68. PubMed ID: 31006077
[TBL] [Abstract][Full Text] [Related]
23. Systemic delivery of factor IX messenger RNA for protein replacement therapy.
Ramaswamy S; Tonnu N; Tachikawa K; Limphong P; Vega JB; Karmali PP; Chivukula P; Verma IM
Proc Natl Acad Sci U S A; 2017 Mar; 114(10):E1941-E1950. PubMed ID: 28202722
[TBL] [Abstract][Full Text] [Related]
24. Human factor IX corrects the bleeding diathesis of mice with hemophilia B.
Kung SH; Hagstrom JN; Cass D; Tai SJ; Lin HF; Stafford DW; High KA
Blood; 1998 Feb; 91(3):784-90. PubMed ID: 9446637
[TBL] [Abstract][Full Text] [Related]
25. Encapsulated human primary myoblasts deliver functional hFIX in hemophilic mice.
Wen J; Xu N; Li A; Bourgeois J; Ofosu FA; Hortelano G
J Gene Med; 2007 Nov; 9(11):1002-10. PubMed ID: 17868187
[TBL] [Abstract][Full Text] [Related]
26. [Conservative management of hemophilic arthropathy].
Müller S; Kurth AA; Hovy L
Orthopade; 1999 Apr; 28(4):347-55. PubMed ID: 10335529
[TBL] [Abstract][Full Text] [Related]
27. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver.
Nathwani AC; Gray JT; Ng CY; Zhou J; Spence Y; Waddington SN; Tuddenham EG; Kemball-Cook G; McIntosh J; Boon-Spijker M; Mertens K; Davidoff AM
Blood; 2006 Apr; 107(7):2653-61. PubMed ID: 16322469
[TBL] [Abstract][Full Text] [Related]
28. Modulating immunogenicity of factor IX by fusion to an immunoglobulin Fc domain: a study using a hemophilia B mouse model.
Levin D; Lagassé HA; Burch E; Strome S; Tan S; Jiang H; Sauna ZE; Golding B
J Thromb Haemost; 2017 Apr; 15(4):721-734. PubMed ID: 28166609
[TBL] [Abstract][Full Text] [Related]
29. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia.
Monahan PE; Samulski RJ; Tazelaar J; Xiao X; Nichols TC; Bellinger DA; Read MS; Walsh CE
Gene Ther; 1998 Jan; 5(1):40-9. PubMed ID: 9536263
[TBL] [Abstract][Full Text] [Related]
30. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.
Wu Z; Sun J; Zhang T; Yin C; Yin F; Van Dyke T; Samulski RJ; Monahan PE
Mol Ther; 2008 Feb; 16(2):280-9. PubMed ID: 18059373
[TBL] [Abstract][Full Text] [Related]
31. Pathogenesis, early diagnosis, and prophylaxis for chronic hemophilic synovitis.
Rodríguez-Merchán EC
Clin Orthop Relat Res; 1997 Oct; (343):6-11. PubMed ID: 9345198
[TBL] [Abstract][Full Text] [Related]
32. Gene therapy for hemophilia B using CB 2679d-GT: a novel factor IX variant with higher potency than factor IX Padua.
Nair N; De Wolf D; Nguyen PA; Pham QH; Samara-Kuko E; Landau J; Blouse GE; Chuah MK; VandenDriessche T
Blood; 2021 May; 137(21):2902-2906. PubMed ID: 33735915
[TBL] [Abstract][Full Text] [Related]
33. Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX.
Ge Y; Powell S; Van Roey M; McArthur JG
Blood; 2001 Jun; 97(12):3733-7. PubMed ID: 11389010
[TBL] [Abstract][Full Text] [Related]
34. Exploring the Potential Feasibility of Intra-Articular Adeno-Associated Virus-Mediated Gene Therapy for Hemophilia Arthropathy.
Zhang F; Yan X; Li M; Hua B; Xiao X; Monahan PE; Sun J
Hum Gene Ther; 2020 Apr; 31(7-8):448-458. PubMed ID: 32079420
[TBL] [Abstract][Full Text] [Related]
35. Efficient AAV1-AAV2 hybrid vector for gene therapy of hemophilia.
Hauck B; Xu RR; Xie J; Wu W; Ding Q; Sipler M; Wang H; Chen L; Wright JF; Xiao W
Hum Gene Ther; 2006 Jan; 17(1):46-54. PubMed ID: 16409124
[TBL] [Abstract][Full Text] [Related]
36. Sustained and therapeutic levels of human factor IX in hemophilia B mice implanted with microcapsules: key role of encapsulated cells.
Wen J; Vargas AG; Ofosu FA; Hortelano G
J Gene Med; 2006 Mar; 8(3):362-9. PubMed ID: 16311997
[TBL] [Abstract][Full Text] [Related]
37. Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA.
Nathwani AC; Davidoff A; Hanawa H; Zhou JF; Vanin EF; Nienhuis AW
Blood; 2001 Mar; 97(5):1258-65. PubMed ID: 11222368
[TBL] [Abstract][Full Text] [Related]
38. Oral gene therapy for hemophilia B using chitosan-formulated FIX mutants.
Quade-Lyssy P; Milanov P; Abriss D; Ungerer C; Königs C; Seifried E; Schüttrumpf J
J Thromb Haemost; 2014 Jun; 12(6):932-42. PubMed ID: 24679056
[TBL] [Abstract][Full Text] [Related]
39. In Utero Transfer of Adeno-Associated Viral Vectors Produces Long-Term Factor IX Levels in a Cynomolgus Macaque Model.
Mattar CNZ; Gil-Farina I; Rosales C; Johana N; Tan YYW; McIntosh J; Kaeppel C; Waddington SN; Biswas A; Choolani M; Schmidt M; Nathwani AC; Chan JKY
Mol Ther; 2017 Aug; 25(8):1843-1853. PubMed ID: 28462816
[TBL] [Abstract][Full Text] [Related]
40. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.
Harding TC; Koprivnikar KE; Tu GH; Zayek N; Lew S; Subramanian A; Sivakumaran A; Frey D; Ho K; VanRoey MJ; Nichols TC; Bellinger DA; Yendluri S; Waugh J; McArthur J; Veres G; Donahue BA
Gene Ther; 2004 Jan; 11(2):204-13. PubMed ID: 14712305
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
